Shanghai Zerun Biotechnology Co.,Ltd

ENGLISH  中文

HPV Vaccine Approved by SFDA for Clinical Trials

Source:2012-07-24

   

In 2011, Zerun's virus like particle based prophylactic human papillomavirus (HPV) vaccine was approved by China State FDA for clinical trials. The vaccine is designed to help vaccinated population to develop immunity against HPV infection which is a major cause of cervical cancer in women, especially for thehigh-risk” HPV type 16 and 18.

Cervical cancer is one of the most common types of cancer in women. World Health Organization data* has shown that there are approximately 500,000 new cases of cervical cancer and 250,000 deaths worldwide annually which makes it the second leading cancer category among women in the world with almost 80% of cases occurring in developing countries. Currently, there are only two HPV vaccines (Mercks Gardasil and GSKs Cervarix) available in the markets outside of China.

Former Merck and Genzymes senior research director, current Zerun Biotech CEO Dr. Li Shi expressed confidence in the HPV project that “Our HPV vaccine product currently undergoing clinical trials will provide quality and affordable alternatives to fight HPV infection and help prevent cervical cancers among women in China and other developing countries”.

 

About Zerun Bio

 

Established in 2003 at the pharmaceutical hub of Shanghai in Zhangjiang Hi-tech Park of Pudong District, Shanghai Zerun Biotechnology Co. Ltd. discovers, develops, manufactures and delivers innovative human vaccines. The company has enjoyed rapid development since its inception through the long term strategic investment of its parent company, Wison Group.

With a broad pipeline of potential new vaccines, Zerun Bio is committed to advancing scientific innovations to dramatically improve people's lives. Zerun has developed the world’s first Vero cell based inactivated Hepatitis A vaccine which has been marketed in China since 2010. Presently, a prophylactic cervical cancer vaccine) developed on a Virus-like Particle technology platform is undergoing clinical trials in China and expected to reach the market in a few years.

 

To learn more about the company, please visit www..

 

CONTACT:

Telephone: 86-21-2030 6789

Fax: 86-21-5889-7229

E-mail: zerunbd@wison.com


*Note: http://www.who.int/mediacentre/news/releases/2006/pr73/en/